Is Atrium Therapeutics, Inc. (RNA) Overvalued?
We dive into why Atrium Therapeutics, Inc. (RNA) could be considered overvalued on 2026-08-18, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Commentary & Analysis
What You Need to Know About Atrium Therapeutics, Inc.'s Q3 Earnings
Atrium Therapeutics, Inc.'s fiscal Q3 earnings report was released on Thursday, August 13. Let's dive in to see if (RNA) missed or beat analyst's expectations.Michael Rose
4 Undervalued Biotechnology Stocks for Friday, June 26
Discover the top 4 undervalued Biotechnology stocks for Friday, June 26 based on AAII’s Stock Grades.Tudor Pop
3 Undervalued Biotechnology Stocks for Monday, May 25
Discover the top 3 undervalued Biotechnology stocks for Monday, May 25 based on AAII’s Stock Grades.Tudor Pop
Why Atrium Therapeutics, Inc.’s (RNA) Stock Is Up 7.03%
As of Thursday, April 23, Atrium Therapeutics, Inc.’s RNA share price has surged by 7.03%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | RNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $236.9 | $298.4 | 29% |
|
| Shares Out (Mil) | 17.1 | 54.0 | 28% |
|
| Institutional Ownership | 96.1% | 93.1% | 69% |
|
| Float (Mil) | 15.1 | 41.4 | 25% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 187 | 504 | 44% |
|
| Price Change (52-week) |
na | 62.0% | na |
|
| Growth | RNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | na | (10.0%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.670) | ($4.550) | ($8.060) | |
| Month Ago EPS | ($0.700) | ($3.590) | ($5.850) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (43.2%) | 42.6% | 102.8% | |
| Financials | RNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $36 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($66) | ($43) | 14% |
|
| EPS (TTM) | ($3.858) | ($1.400) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($53) | ($32) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $73 | $2 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($36) | $186 | 1% |
|
| Valuation | RNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.10 | 2.89 | 25% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | RNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (56.4%) | 64.6% | 2% |
|
| Net Margin | (184.1%) | (75.3%) | 5% |
|
| ROA | (47.1%) | (47.6%) | 12% |
|
| ROE | (86.0%) | (55.0%) | 10% |
|
| Liabilities to Assets | 23.5% | 29.5% | 16% |
|
| F-Score | 1 | 3 | na |
|
Atrium Therapeutics, Inc. did not pass any screens on 8/26/2026.
